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Background: Chest pain is the second most common reason patients visit emergency departments (EDs) and
often results in very low-risk patients being admitted for prolonged observation and advanced cardiac testing.
Shared decision-making, including educating patients regarding their 45-day risk for acute coronary syndrome (ACS)
and management options, might safely decrease healthcare utilization.
Methods/Design: This is a protocol for a multicenter practical patient-level randomized trial to compare an
intervention group receiving a decision aid, Chest Pain Choice (CPC), to a control group receiving usual care. Adults
presenting to five geographically and ethnically diverse EDs who are being considered for admission for observation
and advanced cardiac testing will be eligible for enrollment. We will measure the effect of CPC on (1) patient
knowledge regarding their 45-day risk for ACS and the available management options (primary outcome);
(2) patient engagement in the decision-making process; (3) the degree of conflict patients experience related to
feeling uninformed (decisional conflict); (4) patient and clinician satisfaction with the decision made; (5) the rate of
major adverse cardiac events at 30 days; (6) the proportion of patients admitted for advanced cardiac testing; and
(7) healthcare utilization. To assess these outcomes, we will administer patient and clinician surveys immediately
after each clinical encounter, obtain video recordings of the patient-clinician discussion, administer a patient
healthcare utilization diary, analyze hospital billing records, review the electronic medical record, and conduct
telephone follow-up.
Discussion: This multicenter trial will robustly assess the effectiveness of a decision aid on patient-centered
outcomes, safety, and healthcare utilization in low-risk chest pain patients from a variety of geographically and
ethnically diverse EDs.
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Chest pain is the second most common reason patients
visit emergency departments (EDs) across the United
States, accounting for over 8 million visits and 25% of
hospital admissions annually [1,2]. Information from
the history and physical examination, electrocardiogram,
and initial cardiac troponin alone lack sufficient sensitivity
to reliably eliminate patients without acute coronary
syndrome (ACS) who are safe for ED discharge. As
missed ACS may lead to an acute myocardial infarction
(AMI) and/or potentially preventable death or disability,
clinicians have a low threshold to hospitalize patients
with chest pain. This results in increased psychological
morbidity for patients - including anxiety and depression -
and hospital overcrowding, increased false positive test
results, unnecessary downstream procedures, and between
3 and 10 billion dollars spent annually for patients found
not to have cardiac disease [3,4].
Several contemporary prediction rules for ED patients
with possible ACS have been developed and validated
[5-9]. To date, however, none have been widely adopted
by clinicians and consistently translated into practice. A
recent trial suggests that it may be feasible to discharge
low-risk patients with possible cardiac chest pain from
the ED without cardiac stress testing or a computed
tomography (CT) coronary angiography [10]. However,
ED patients being evaluated for possible ACS are rarely
aware of their risk for an adverse cardiac event, [11] and
in one recent trial lower patient satisfaction was observed
in the intervention arm in which clinicians used evidence-
based decision support without explicit risk communica-
tion and patient engagement [12].
In the context of emergency medicine, clinicians fre-
quently practice under conditions of high patient volume
and acuity and are often required to make decisions ex-
peditiously to ensure the safety of patients waiting to be
seen. The approach clinicians take to medical decision-
making may vary based on any number of factors, such
as the degree of patient acuity, the cognitive workload
of the clinician at a particular moment in time, and
their perception of a patient’s desire to engage in deci-
sions regarding their care, among others. Moreover, the
approach adopted at the onset of a medical encounter
may change as the interaction evolves [13]. One way to
think of this is as a fluid process, in which an experienced
clinician seamlessly transitions from one decision-making
model to the next, depending on the approach that
seems most appropriate given the clinical context and
the individual patient.
In prior work we developed a decision aid, Chest Pain
Choice (CPC), [14] and tested the hypothesis that use of
the decision aid during a clinical encounter would facili-
tate a shared approach to medical decision-making, im-
prove patient-centered decision-based outcomes (patientknowledge, engagement in the decision-making process
and satisfaction), and safely decrease resource utilization.
The decision aid described to patients the rationale for
their chest pain evaluation and the potential utility of
urgent cardiac stress testing. It also included a precise
estimate of the 45-day risk for ACS derived from a robustly
validated prediction model [5,15,16] and communicated
that risk using prose phrases, numbers, and a pictograph to
account for the patient’s preferred mode of understanding
numerical information [14]. In a single-center randomized
pilot trial (n = 204) we observed greater knowledge re-
garding management options and the short-term risk
for ACS, greater engagement in the decision-making
process, and a 19% lower rate of observation unit ad-
mission for cardiac stress testing in patients randomized
to this shared decision-making intervention compared
to usual care, and there were no major adverse cardiac
events within 30 days in either arm [11].
In this paper we describe the rationale and methods
employed to test the effectiveness of the CPC decision
aid in a multicenter trial in five geographically and eth-
nically diverse hospital EDs in the United States. We
hypothesize that use of the decision aid will significantly
increase patient knowledge, engagement and satisfaction,
and decrease the rate of testing that may have marginal
benefit in the low-risk population with no increase in
adverse events.
Methods/Design
This practical, multicenter randomized trial compares an
intervention group receiving a structured risk assess-
ment and corresponding decision aid (CPC), to a control
group receiving usual care [17]. Institutional Review
Board approval has been obtained at each participating
institution. The trial is registered at clinicaltrials.gov
(NCT01969240).
Setting
Patients and physicians will be recruited from five EDs:
the University of Pennsylvania in Pennsylvania, United
States (east coast with an urban patient population); the
Mayo Clinic in Rochester, Minnesota, United States
(midwest with a rural patient population); the Mayo
Clinic in Jacksonville, Florida, United States (southeast
with an urban patient population); the University of
California, Davis in California, United States (west coast
with an urban patient population); and Indiana Univer-
sity Health Methodist Hospital in Indianapolis, Indiana,
United States (midwest with an urban patient population).
We selected these five settings to assess the effectiveness
of the decision aid in geographically diverse clinical
practice contexts and ethnically diverse patient popula-
tions. The trial will be conducted in the flow of routine
patient care.
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Participant recruitment
A study coordinator will identify potentially eligible pa-
tients based on the chief complaint and, in collaboration
with the treating clinician, confirm patient eligibility for
the trial (Figure 1). The study coordinator will then ob-
tain written informed consent from the patient. Consent
will be obtained from participating clinicians before or
at the time of patient consent. Patients will be consecu-
tively enrolled at each of the participating centers six to
seven days per week whenever a study coordinator is
available for enrollment.Eligibility criteria
Eligible clinicians will include ED physicians and mid-level
providers caring for patients with chest pain. Eligible pa-
tients will include adults (>17 years of age) presenting to
the ED with a chief complaint of chest pain who are being
considered by the treating clinician for admission for add-
itional observation and cardiac stress testing or for further
cardiac testing with coronary CT angiography. Exclusion
criteria are listed in Figure 1. Data will be collected on all
patients assessed for eligibility, including the number of
excluded patients, the rationale for each exclusion, and
the number of patients who decline consent to participate
in the study in accordance with the CONSORT guidelines
for reporting randomized trials [18].Integrating patient recruitment, consent, and delivery of the
intervention in the flow of patient care
Figure 1 shows how the process of patient recruitment,
consent, randomization, and delivery of the intervention
will integrate with the flow of patient care. We will at-
tempt to assess patient eligibility and obtain consent
shortly after the clinician has evaluated the patient and
interpreted the initial ECG, but before the result of the
first cardiac troponin is available. Patients who are
otherwise eligible for the study but in whom the first
cardiac troponin result is greater than the 99th percentile
reference limit will be excluded prior to randomization.
Once the initial cardiac troponin result is determined to
be negative, the patient will subsequently be randomized
using a centralized web-based mechanism to either the de-
cision aid or usual care arm. Patients who are randomized
to the decision aid arm will then discuss with their clin-
ician their 45-day risk for an adverse cardiac event and
engage in shared decision-making. Patients randomized
to usual care will receive no intervention. The number
and timing of subsequent cardiac troponin measurements
will not be prescribed by the study protocol. Instead pa-
tients will subsequently undergo serial cardiac troponin
measurements to rule out AMI according to the insti-
tutional protocol at each participating site.Patient and stakeholder engagement in the trial
Patients, their caregivers, and other key stakeholders
were and will be engaged throughout the entire research
process and will comprise the patient and stakeholder
advisory group.
The emergency department Patient Advisory Council,
which consists of five individuals who have contributed
the patient’s perspective to several practice and quality
improvement initiatives at Mayo Clinic Rochester -
an ED quality specialist, three patients, and a nurse
representative - provided feedback on the grant proposal
and will continue to inform on the conduct of the trial
and the interpretation of the results when the trial is
complete. A patient and caregiver representative were
engaged in the preparatory phases of research and
assisted in the development and iterative refinement of
the CPC decision aid, provided feedback on the grant
proposal submitted for funding, selected the primary
outcome for study, are active members on the investiga-
tive steering committee, and participate in the study as
co-investigators. We will also engage the patient and
caregiver representatives in the interpretation and dissem-
ination of the study findings once the trial is complete.
Randomization
Patients will be randomized after informed consent is
obtained and it is confirmed that all inclusion and no
exclusion criteria are met, prior to the patient-clinician
discussion of treatment options and patient risk. Alloca-
tion will be concealed by means of an online password-
protected randomization algorithm designed using Medi-
data Balance™ Medidata Solutions, New York City, USA.
Patients will be dynamically stratified [19] by enrolling by
site, age and sex because of the known association of age
and sex with cardiovascular risk and the availability of
these data at the time of enrollment. Allocation will be
based on a 1:1 ratio between the intervention and usual
care arms. Though we will not be able to blind patients
and clinicians to use of the decision aid, we will blind the
investigators and individuals not involved in providing
care to the patient allocation.
Intervention arm
Refinement of the decision aid
The initial CPC decision aid was developed and tested in
a single-center pilot randomized trial at the Mayo Clinic
in Rochester, Minnesota, United States, as described pre-
viously [11]. The process of decision aid development
was evidence-based, iterative, involved patients and key
stakeholders, was based on participatory action research,
used design approaches to ensure the final iteration met
the needs of end-users, and resulted in a tool that sat-
isfied International Patient Decision Aid Standards
(IPDAS) [20]. After the pilot trial was completed and
Figure 1 Flow diagram showing the integration of study procedures in the flow of patient care. *Candidacy for ED observation unit
admission will be assessed after the results of the initial troponin are available in some cases. CTCA, computed tomographic coronary angiography;
ED, emergency department; CAD, coronary artery disease; ECG, electrocardiogram.
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underwent additional revisions based on input from the
patient (MD) and caregiver (AL) representatives engaged
in the trial and the investigative team in order to increase
the clarity of the decision aid and improve patient com-
prehension. The refined CPC one-page decision aid is
included in Figure 2.
In the process of preparing for the trial it became
clear that one of the participating sites (University of
Pennsylvania) frequently used coronary CT angiography
in chest pain patients at low-risk for ACS in lieu of car-
diac stress testing. To ensure the decision aid facilitated
a conversation that included options relevant to the set-
ting in which patients are frequently considered for coron-
ary CT angiography, a second version of the decision aid
was developed for use at this site (Figure 3).
Participating clinicians were trained by means of a one-
hour grand rounds presentation given by the lead investi-
gator at each participating site, as well as a training videoFigure 2 The Decision Aid. The decision aid describes for patients the rat
(electrocardiogram, initial cardiac troponin level) and the potential utility of
coronary syndrome within 45 days, obtained from a quantitative pretest pr
[5,15,16], is included. The decision aid will be individualized to the patient
displayed using a state-of-the-art risk communication pictograph using an
description of patient risk (for example, out of every 100 patients with facto
45 days, 99 did not) to account for differences in numeracy preferences be
options (admission with urgent cardiac stress testing, follow-up with a cardiol
or have the clinician make the decision on the patient’s behalf) for the cliniciathat demonstrated use of the decision aid in a simulated
patient encounter. The lead study coordinator at the cen-
tral coordinating site trained each of the study coordina-
tors at the participating sites to ensure comprehension of
the study protocol and the standardized execution of study
procedures. As was done in our pilot trial, study coordina-
tors will offer to provide the treating clinician a concise re-
fresher of the content included in the decision aid at the
time of patient enrollment. Videos of the patient-clinician
disposition discussion will be obtained to assess the fidelity
of the use of the decision aid in the intervention group
and to monitor for contamination in the control group.
Video and audio recordings will be consented to separ-
ately and are not required for participation in the trial.
Delivery of the intervention
For patients randomized to the decision aid arm, the study
coordinator will collect each of the variables entered
into the quantitative pretest probability (QPTP) PREtestionale for, and results of, the initial emergency department evaluation
additional cardiac testing. A reliable estimate of the risk of an acute
obability (QPTP) web-tool developed and tested by Kline et al.
based on the results of the QPTP risk calculator. The risk estimate is
ordered icon array displaying natural frequencies, and a prose
rs like yours, 1 had a heart attack or pre-heart attack diagnosis within
tween patients. The decision aid also provides explicit management
ogist or the patient’s own primary care physician within 24 to 72 hours,
n and patient to consider when reaching a shared decision.
Figure 3 Decision aid that includes the option of coronary CT angiography. This version of the decision aid was developed for use at the
University of Pennsylvania emergency department (Pennsylvania, United States) in which coronary CT angiography is frequently used in lieu of
cardiac stress testing.
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clinician to verify and sign off on their accuracy, gener-
ate the 45-day estimate of ACS risk, and select the deci-
sion aid corresponding to the appropriate level of risk.
The study coordinator will then provide the clinician
with a color copy of the decision aid prior to the dispos-
ition discussion with the patient and offer to provide a
concise refresher of the content included in the decision
aid. The treating clinician will then, using the decision
aid as a tool to facilitate discussion, educate the patient
regarding the rationale for their evaluation up to that
point in the ED visit, communicate the 45-day risk for a
heart attack or pre-heart attack, and engage the patient
in a shared decision regarding whether to obtain further
cardiac testing after AMI has been ruled out by cardiac
troponin testing, to follow up as an outpatient within
72 hours of the ED visit with a cardiologist or their pri-
mary care physician, or to have the emergency clinician
decide on the patient’s behalf.
Usual care
For patients randomized to the usual care arm the clinician
will discuss the results of diagnostic investigations and
management options with the patient in that clinician’susual fashion. The patient’s risk will be calculated using
the QPTP calculator for study purposes, however, the pa-
tient and clinician will be blinded to the QPTP-structured
risk assessment and the corresponding decision aid in
this arm. As in the intervention arm, the clinician-patient
disposition discussion will be video and audio recorded
to assess the degree to which the clinician engages the
patient in the decision-making process and to monitor
for contamination in the control arm.
Outcome measures
When selecting outcome measures we obtained input from
a patient and caregiver representative, clinicians (emer-
gency medicine clinicians and cardiologists), researchers
(health services researchers and shared decision-making
experts), and a payer representative (Chief Medical Officer
of Mayo Clinic Health Solutions). In face-to-face meetings
with the patient and caregiver representative it became
clear that knowledge was the outcome that was of great-
est interest to the patient, so patient knowledge was se-
lected as the primary outcome. Thus, as we did in our
pilot trial, we will assess patient’s knowledge regarding
their short-term risk for ACS, the potential implications
of cardiac testing, the available management options,
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post-visit survey administered immediately after the
clinical encounter [11].
We will also assess a number of secondary outcomes,
including patient engagement in the decision-making
process, as measured by the OPTION (observing patient
involvement) scale [21]; the degree of conflict patients
experience related to feeling uninformed, as measured
by the Decisional Conflict Scale (DCS) [22]; trust in the
physician measured via the Trust in Physician Scale
(TPS) [23]; patient satisfaction with the decision made,
via a Likert scale on the post-visit survey; and safety as
determined by the prevalence of Major Adverse Cardiac
Events (MACE) within 30 days of the ED visit.
Consistent with recommendations in a recently pub-
lished consensus document on ACS research in emer-
gency departments [24], we will define MACE as AMI
[25], death due to a cardiac or unknown cause, emergency
revascularization, ventricular arrhythmia, or cardiogenic
shock. We will exclude MACE that occurs during the
index admission to the ED but rather focus on events
occurring after discharge, in the outpatient setting,
which could have potentially been avoided or diagnosed
in the ED or hospital. This approach avoids having to
adjudicate whether MACE occurring in the ED or
hospital were ‘missed’ based on a post-hoc review of po-
tentially incomplete medical records. We will collect
data on all MACE that occur up to 45 days from the
index ED visit as this is the follow-up interval assessed
by the QPTP instrument [5,15,16]. However, we will
compare rates only for events that occur prior to or at
30 days in order to comply with standardized reporting
guidelines for risk stratification of ED patients with pos-
sible ACS and to facilitate comparison with other ACS
risk stratification studies in the extant literature [26]. A
subsequent analysis for all 45 days is planned, with
these data to be included as part of an Additional file.
To account for differences in troponin assays between
institutions, and for the potential of changing from one
assay to another in a given institution during the trial,
we will track the specific cardiac troponin assay used at
each institution along with that assay’s characteristics
(lower limit of detection, 99th percentile reference limit,
and 10% coefficient of variation), the absolute value of
each troponin measurement, the upper limit of normal
used at that institution, and classify whether that value is
above the upper limit of normal in each enrolled patient
(Additional file 1). Three investigators blinded to the
study arm will adjudicate all potential MACE cases and
discordances will be noted and resolved by consensus.
One of the goals of this study is to measure the effect
of CPC on healthcare utilization. Healthcare utilization
will be assessed by measuring the proportion of patients
admitted for cardiac testing, the most immediate clinicaldecision and the greatest driver of utilization, and the
patients’ healthcare utilization for the subsequent 30 days
after the ED encounter. This will include measures such
as hospitalization, re-hospitalization, primary, specialty,
and ED visits, and diagnostic and laboratory testing.
Data collection
Data documenting the process of screening for poten-
tially eligible participants, application of the eligibility
criteria (including the reason for each exclusion), the
variables entered into the pretest probability calculator,
the arm to which each patient is randomized, and other
information best collected in real time will be recorded
by study coordinators using a standardized case report
form (Additional file 2). Patients’ preferences for under-
standing numerical information and their preferred ap-
proach to participation in medical decision-making will
be assessed by a survey administered prior to the clinical
encounter (Additional file 3).
Immediate post-visit surveys will collect data on patient
knowledge, decisional conflict, patients’ trust in their
physician, and patient satisfaction with the decision
made (Additional file 4). The degree to which clinicians
engage patients in the decision-making process will be
assessed by having two trained team members independ-
ently review videos of the clinician-patient disposition
discussion and apply the OPTION scale [21].
The patient will be contacted 45 days after enrollment
via telephone (primary method of contact) for assessment
of safety. If the primary method of contact is not success-
ful the study coordinator will subsequently contact the pa-
tient utilizing a secondary method of contact specified by
the patient at the time of consent (such as email, a second-
ary phone number, or mail) for a follow-up assessment.
Safety will be assessed using a standardized phone follow-
up script to determine whether a MACE occurred and, if
so, the date of the event (Additional file 5). Events occur-
ring within 45 days will be recorded to ensure consistency
with the duration of follow-up used in the development of
the QPTP instrument [15] and MACE within 30 days will
be reported in accordance with standardized reporting
guidelines for risk stratification studies of ED patients with
potential ACS [26].
Utilization data will be collected from the electronic
medical record at each site, patient self-report, and UB-92
and UB-04 summary hospital billing statements. Whether
the patient was admitted to the observation unit or hos-
pital and/or underwent advanced cardiac testing such as
cardiac stress testing, coronary CT angiography, or percu-
taneous coronary angiography, will be assessed by review
of the electronic medical record at each institution. Pa-
tients will be given a healthcare utilization diary at the
time of ED discharge (Additional file 6) and educated
regarding its use to facilitate the standardized collection
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billing statements. Any entries in the healthcare diary,
including the date and location of service, will be ascer-
tained at the time of 45-day follow-up. Healthcare
utilization within 30 days of the ED visit will be reported
for study purposes.
Clinicians will be surveyed immediately after each en-
counter to determine their perception of the degree of pa-
tient involvement in the decision, the helpfulness of the
information provided to the patient, and other characteris-
tics of the decision-making process (Additional file 7).
Study data will be collected and managed using REDCap
(Research Electronic Data Capture) tools hosted at the
Mayo Clinic [27]. REDCap is a secure, web-based appli-
cation designed to support data capture for research
studies, providing: 1) an intuitive interface for validated
data entry; 2) audit trails for tracking data manipulation
and export procedures; and 3) automated export proce-
dures for seamless data downloads to common statis-
tical packages.
An independent data and safety monitoring board
(DSMB) will monitor safety, scientific, and ethical aspects
of the study. The DSMB met prior to beginning enrollment
and will meet every six months throughout the duration of
the study. Though every effort will be made to minimize
post-randomization exclusions, patients will be excluded
after randomization if they are found to meet exclusion cri-
teria that were not recognized at the time of enrollment or
they choose to withdraw [28]. Any potential MACE follow-
ing discharge from the ED or hospital will be reported to
the principal investigator and the DSMB. The authority to
stop the study will be retained by the DSMB and must be
based on consensus.
Statistical considerations
In order for the study findings to maximally impact
practice and policy, they will need to be adequately pow-
ered to detect differences in outcomes of interest to eachTable 1 Anticipated power to detect patient and stakeholder
Outcome (n = 884) Us
Patient knowledge 44
Patient engagement in the decision-making process (n = 221) 7.0
Decisional conflict† 35
Trust in the physician 79
Patient satisfaction with the decision made (% agree or
strongly agree they are satisfied)
69
Safety (major adverse cardiovascular events)‡ 0%
Proportion of patients admitted for cardiac testing 77
Healthcare utilization 8.3
*Estimates were determined from our completed pilot randomized trial [11].
†Lower decisional conflict scores indicate less conflict experienced by patients relat
‡Non-inferiority, one-sided test with alpha = 0.05 with a maximum difference of 5%of the stakeholders (patients, clinicians, shared decision-
making research experts, and healthcare payers). We will
have sufficient funding to enroll 930 patients, accounting
for a loss to follow-up rate as high as 5% (there was 2%
lost to follow-up in our pilot trial) [11], we anticipate
having complete data on 884 patients. Table 1 shows the
anticipated power we will have to detect differences in
each of the patient and stakeholder-important outcomes
on completion of the trial.
We will use standard techniques appropriate for
patient-randomized trials, with each outcome compared
between study arms using t-tests for continuous outcomes
and chi-square tests for dichotomous outcomes. Rather
than assume the intervention effect is independent of
the study site where the patient is seen or of the clin-
ician who sees them, we will assess intra-site and intra-
clinician correlations. We will then stratify all tests on
the study site unless the intra-clinician correlation is
non-trivial, in which case we will stratify on a clinician
basis. We will calculate differences and their confidence
intervals using standard techniques for continuous and
dichotomous data. If there are differences in baseline
characteristics between the two study groups, these will
be accounted for using regression models that will in-
clude an indicator for study arm. Finally, we will analyze
clinician surveys using regression models with robust
standard errors to account for the repeated measures
on clinicians.
Descriptive analyses will be performed to describe any
potential heterogeneity of treatment effect (HTE) and
facilitate synthesis of subgroup results in future meta-
analyses. We will conduct descriptive HTE analyses by
age, gender, race/ethnicity, quantitative pre-test prob-
ability of ACS, level of education, OPTION scores, and
study site. The outcomes assessed with HTE analyses
will be the same as those assessed in the trial (such
as knowledge, engagement, satisfaction, and healthcare
utilization). We will also conduct interaction testing to-important outcomes on completion of the trial
ual Care* Decision Aid* Difference Power
% (23.3) 60% (20.9) 16% (9.5%, 22.5%) 99%
(5.5) 26.3 (8.2) 19.3 (18.4, 20.2) 99%
.9 (18.9) 22.3 (21.1) 13.6 (11.0, 16.2) 99%
.3 (19.9) 83.4 (19.8) 4.1 (1.5, 6.7) 86%
.7 (25.6) 80 (25.6) 10.3 (4.6%, 16.0%) 99%
0% 0% (−−) 78%
% 67% 10% (4.1, 15.9) 90%
(0.8) 7.0 (0.7) 1.3 (1.2, 1.4) 99%
ed to feeling uninformed.
.
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each pre-specified characteristic.
Resource use will be compared both descriptively and
using multivariable models. Descriptive comparison for
30-day utilization will utilize the Wilcoxon rank-sum
test to account for the skewness of the outcome mea-
sures. The multivariable models for resource utilization
will be estimated using the two-part or one-part negative
binomial or log gamma regression models. A two-part
model will be utilized for outcomes where more than
10% of the subjects have a zero outcome measure. The
covariates in the multivariable models will include fac-
tors that may not be accounted for in the randomization
such as comorbidities and severity of illness. Comorbidi-
ties will be measured using the Elixhauser method, which
is a commonly used measure for the acute setting [29].
We will also analyze the results using a subset of patients
who primarily receive their entire healthcare at the par-
ticipating centers. We expect that this analysis will pro-
vide a sensitivity analysis of the overall trial results
based on self-report.
Discussion
We have described the rationale and methodology for a
multicenter randomized clinical trial to measure the ef-
fectiveness of a decision aid on validated patient-centered
outcome measures, safety, and healthcare utilization in ED
chest pain patients at low-risk for ACS. The trial repre-
sents a dynamic and ongoing collaboration between a pa-
tient and caregiver representative, the ED patient advisory
council at Saint Mary’s Hospital in Rochester (Minnesota,
United States), ED clinicians, shared decision-making
experts, a cardiologist, and health services researchers
and will be the first multicenter shared decision-making
trial conducted in an ED setting. If findings from our
single-centered randomized trial [11] are externally vali-
dated in a variety of hospital EDs, it will also serve as
proof of concept that can subsequently be applied to
other emergency conditions and lay the groundwork for
future implementation studies to explore how to best
incorporate shared decision-making as part of routine
clinical care in the emergency setting.
An important reason to conduct feasibility trials of
decision aids designed for use in the clinical setting is
that the tools have potential to impact the nature and
content of the patient-clinician discussion as well as the
duration of the clinical evaluation. Although it was not
a significant barrier to patient engagement in our pilot
trial, patients who present to the ED with chest pain
may be in a vulnerable emotional state such that they
might prefer decisions be made on their behalf rather
than actively participate in their medical care. The ED is
also the safety net for patients of all levels of education
and for those without medical insurance, and weanticipate that there may be knowledge transfer chal-
lenges unique to this practice setting. When clinicians
with different practice patterns and levels of experience
use the decision aid they may not find it appropriate to
use for some patients, or may not use the decision aid
appropriately. Therefore, video recording the patient-
clinician encounter may provide insight into these po-
tential challenges, the effectiveness of the decision aid,
and the nature of the patient-clinician interaction in a
busy ED environment.
Randomizing at the patient level increases the risk of
contamination between the intervention and control
arms. We have taken several steps to minimize the risk
of contamination. First, the 45-day ACS risk calculator
is password protected and clinicians will not be able to
determine an individual patient’s risk of ACS using this
instrument, or have access to the decision aid [16]. Fur-
thermore, in our pilot trial, we observed that when clini-
cians did not have access to the decision aid and patients’
45-day risk of ACS, they reverted back to their usual prac-
tice of rapid decision-making and limited discussion with
patients and were reticent to engage patients in shared
decision-making. Second, only the site coordinators will
have access to copies of the decision aid, and clinicians
will not be provided the decision aid in the usual care
arm. Third, site coordinators have been carefully trained
to confirm the accuracy of each of the variables needed to
generate the 45-day ACS risk estimate by review and sign-
off by the treating clinician, but are instructed to keep the
clinician blind to a patient’s risk unless a patient is ran-
domized to the decision aid. Fourth, every effort will be
made to obtain video and audio data of the disposition
discussion in both the intervention and control arms, and
we will monitor for contamination by review of these data.
Finally, if contamination does occur, we anticipate it will
decrease the magnitude of differences observed in the
intervention and control groups, biasing the results to-
wards the null.
There are advantages and disadvantages to using two
different decision aids in the context of this trial. Having
a separate decision aid (Figure 2) for the site in which
coronary CT angiography is routinely used in lieu of
cardiac stress testing in low-risk chest pain patients in-
troduces heterogeneity in the intervention. However, a
key aspect of contemporary evidence-based medicine
involves translating evidence into practice in a manner
that is sensitive to local practice context [30] as well as
patients’ values and preferences [31], and our decision
to design two different decision aids reflects an under-
lying commitment to these values. In addition, a key
goal of the decision aid is to generate a conversation
about the evidence surrounding a management decision
and, by necessity, the conversation must include the
management options frequently used in that practice
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Finally, we plan to measure the effect of the interven-
tion both overall and by site, which will provide insight
into any differences in effectiveness between sites.
It is possible that not all of the clinicians at each site
will be willing to participate in the trial. This has the po-
tential to decrease the rate of recruitment. However, in
our pilot trial over 90% of the clinicians at our site
agreed to participate [11], and the majority of the sites
participating in the trial have a track record of successfully
recruiting ED chest pain patients for prospective research,
therefore we anticipate a high degree of clinician support
and participation in the study.
In conclusion, this trial will compare the effectiveness
of a shared decision-making approach to usual care in
patients with low-risk chest pain presenting to the ED
for evaluation. Such an approach has the potential to
safely tailor advanced cardiac testing to the degree of
patient risk in a manner that educates and empowers
patients to participate in the decision-making process,
is consistent with patients’ values and preferences, and
is supportive of clinicians’ knowledge and expertise.
Trial status
The study began enrolling patients in October 2013.
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